Simultaneous pancreas-kidney transplantation: analysis of rejection.

Malaise, Jacques;Arbogast, H.;Illner, W. D.;Tarabichi, A.;Squifflet, Jean-Paul;et.al.
(2005) Transplantation Proceedings — Vol. 37, n° 6, p. 2856-2858 (2005)

Files

29470.pdf
  • Restricted Access
  • Adobe PDF
  • 64.18 KB

Details

Authors
  • Malaise, JacquesUCLouvain
    Author
  • Arbogast, H.UCLouvain
    Author
  • Illner, W. D.UCLouvain
    Author
  • Tarabichi, A.UCLouvain
    Author
  • Dieterle, C.UCLouvain
    Author
  • Landgraf, R.UCLouvain
    Author
  • Land, W.UCLouvain
    Author
  • Squifflet, Jean-PaulUCLouvain
    Author
Show more
Abstract
The 3-year data concerning the occurrence of rejection episodes (RE) are reported herein. PATIENTS AND METHODS: Two hundred five simultaneous pancreas-kidney (SPK) transplantations were performed from May 1998 to September 2000, including 103 patients randomly assigned to tacrolimus (Tac) and 102 to cyclosporine microemulsion (CsA-ME). All patients received concomitant rATG induction therapy, mycophenolate mofetil (MMF), and short-term corticosteroids. RESULTS: After a follow-up of 3 years, acute rejection episodes occurred in 41 patients receiving tacrolimus and in 51 patients receiving CsA ME. The majority of first rejection episodes in both groups occurred during the first 6 months (93% and 90%, respectively) and in most cases were treated with corticosteroids (88% and 90%). Actuarial rejection-free graft survival was not significantly different between the two groups (54% and 44% at 3 years posttransplant). In a multivariate analysis, HLA compatibility (P = .003) and graft vessel extension (P = .0005) had a significant influence on rejection-free survival. Rejection influenced pancreatic graft survival (P = .01) and pancreatic graft loss owing to rejection influenced patient survival (P = .02). In the intent-to-treat analysis of early rejection, first moderate-to-severe episodes (1 of 40 versus 12 of 47; P = .004) and refractory episodes (2 of 40 versus 10 of 47; P = .03) were significantly lower with tacrolimus than with CsA ME. Pancreatic graft survival was worse among late rejectors (53%) than nonrejectors (86%; P = .002). In addition, serum creatinine was highest in late rejectors. In conclusion, Tac-based immunosuppressive therapy shows advantages over CsA ME in terms of the severity of acute rejection episodes among patients undergoing SPK transplantation.
Affiliations

Citations

Malaise, J., Arbogast, H., Illner, W. D., Tarabichi, A., Dieterle, C., Landgraf, R., Land, W., Van Ophem, D., & Squifflet, J.-P. (2005). Simultaneous pancreas-kidney transplantation: analysis of rejection. Transplantation Proceedings, 37(6), 2856-2858. https://doi.org/10.1016/j.transproceed.2005.05.027 (Original work published 2005)